Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non small-cell lung cancer cell lines

British Journal of Cancer

Volumn 80, Issue 7, 1999, Pages 981-990

  Van Moorsel, C J A ^a   Pinedo, H M ^a   Veerman, G ^a   Bergman, A M ^a   Kuiper, C M ^a   Vermorken, J B ^a   Van Der Vijgh, W J F ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cisplatin; DNA adducts; DNA damage; Gemcitabine; Strand breaks

Indexed keywords

CISPLATIN; GEMCITABINE; PLATINUM;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA REPAIR; DRUG DNA BINDING; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CISPLATIN; DEOXYCYTIDINE; DNA; DNA ADDUCTS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLUOROMETRY; HUMANS; INTRACELLULAR FLUID; LUNG NEOPLASMS; MICE; OVARIAN NEOPLASMS; PLATINUM; RNA; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032958512     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690452     Document Type: Article

References (38)

1. Abbruzzese JL and Frost P (1992) Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chem Pharmacol 30: 31-36
2. Abbruzzese JL, Grunawald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN and Plunkett W (1991) A phase 1 clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498
3. Abratt RP, Bezwoda WR, Goedhals L and Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15: 744-749
4. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM and Peters GJ (1996) Interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
5. Birnboim HC and Jeveak JJ (1981) Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res 41: 1889-1892
6. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP and Peters GJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 1335-1340
7. Chiu CSM, Chan AK and Wright JA (1992) Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Biochem Cell Biol 70: 1132-1338.
8. Chou T-C and Hayball MP (1996) CalcuSyn, Windows Software for Dose Effect Analysis. Biosoft: Cambridge
9. Chou T-C and Talalay P (1983) Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs on enzyme inhibitors. In Advances in Enzyme Regulation, G. Weber (ed), pp. 27-55. Pergamon Press: New York
10. Chou T-C, Motzer RJ, Tong Y and Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth; a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524
11. Crino L, Scagliotto G, Marangolo M, Figoli F, Clerici M, DeMarinis F, Salvati F, Cruciani G, Dagliotti L, Pucci F, Paccagnella A, Adamao V, Altavilla G, Incoronato P, Tripetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 15: 297-303
12. Ellerhorst JA, Frost P, Abbruzzese JL, Newman RA and Chernajovsky Y (1993) 2′-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 67: 209-215
13. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R and Allerheiligen SRB (1995) Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid-chromatography with ultraviolet detection. J Chromatogr Biomed Appl 665: 171-181
14. Heinemann V, Hertel LW, Grindey GB and Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031
15. Hertel LW, Kroin JS, Misner JW and Tustin JM (1988) Synthesis of 2′-deoxy-2′,2′-difluoro-D-ribose and 2′-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53: 2406-2409
16. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
17. Krakowski I, Petit T, Kayitalire L, Weber B, Beaudouin M, Canon JL, Janssens J, Martin C and Belpomine D (1998) Gemcitabine (Gemzar) in combination with cisplatin (CP) in advanced ovarian cancers (AOC): a phase II study. Proc Am Soc Clin Oncol 17: 356a (abstract 1373)
18. Lu Y, Han J and Scanlon RJ (1988) Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem 263: 4891-4894
19. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 761-766
20. Nogué M, Cirera L, Arcusa M, Tusquets I, Batiste-Alentorn E, Font A and Boto B (1998) Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 17: 357a (abstract 1377)
21. Parker RJ, Gill I, Tarone R, Vionnet J, Grunberg S, Muggia F and Reed E (1991) Platinum DNA-damage in leucocyte DNA of patients receiving cisplatin and carboplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 12: 1253-1258
22. Peters GJ, Laurensse E, Leyva A and Pinedo HM (1987) Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 23: 1869-1881
23. Peters GJ, Wets M, Keepers YPAM, Oskam R, Van Ark-Otte J, Noordhuis P, Smid K and Pinedo HM (1993a) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54: 450-455
24. Peters GJ, Schomagel JH and Milano GA (1993b) Clinical pharmacokinetics of anti-metabolites. Cancer Surveys 17: 123-156
25. Ruiz van Haperen VWT, Veerman G, Vermorken JB and Peters GJ (1993) 2′,2′-Difluoro-deoxocytidine (Gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 762-766
26. Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M, Vermorken JB, Pinedo HM and Peters GJ (1994a) Development and characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res 54: 4138-4143
27. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB and Peters GJ (1994b) Schedule-dependence of sensitivity to 2′,2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 48: 1327-1339
28. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM and Peters GJ (1996) Regulation of deoxycytidine kinase from solid tumor cell lines by CTP and UTP. Biochem Pharmacol 51: 911-918
29. Scanlon KJ, Kashai-Sabet M, Tone T and Funato T (1991) Cisplatin resistance in human cancers. Pharmacol Ther 52: 385-406
30. Steward WP, Dunlop DJ, Dabouis G, Lacroix H and Talbot D (1996) Phase I/II study of gemcitabine and cisplatin in non-small cell lung cancer: preliminary results. Semin Oncol 5: 43-47
31. Sundquist WI and Lippard SJ (1990) The coordination chemistry of platinum anticancer drugs and related compounds with DNA. Coord Chem Rev 100: 293-322
32. Terheggen PMAB, Emondt JY, Floot BGJ, Dijkman R, Schrier PI, Den Engelse L and Begg AC (1990) Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 50: 3556-3561
33. Van der Vijgh WJF (1991) Clinical pharmacology of carboplatin. Clin Pharmacokin 21: 242-261
34. Van der Wilt CL, Smid K, Noordhuis P, Aherne GW and Peters GJ (1997) Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 33: 471-478
35. Van der Wilt CL, Visser GWM, Braakhuis BJM, Wedzinga R, Noordhuis P, Smid K and Peters GJ (1993) In vitro antitumour activity of cis-and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils. Br J Cancer 68: 702-707
36. Van Moorsel CJA, Peters GJ and Pinedo HM (1997) Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2: 127-134
37. Van Moorsel CJA, Pinedo HM, Veerman G, Vermorken JB, Postmus PE and Peters GJ (1999) Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice. Eur J Cancer. In press
38. Vermorken JB, Van der Vijgh WJF, Klein I, Gall HE, Van Groeningen CJ and Pinedo HM (1984) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39: 136-144